Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 513

1.

PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy.

Jacot W, Dalenc F, Lopez-Crapez E, Chaltiel L, Durigova A, Gros N, Lozano N, Lacaze JL, Pouderoux S, Gladieff L, Romieu G, Roché H, Filleron T, Lamy PJ.

Breast Cancer Res Treat. 2019 Jul 11. doi: 10.1007/s10549-019-05349-y. [Epub ahead of print]

PMID:
31297647
2.

Effects of dietary fat on insulin secretion in subjects with the metabolic syndrome.

Gulseth HL, Gjelstad IMF, Tiereny AC, McCarthy D, Lovegrove JA, Defoort C, Blaak EE, Lopez-Miranda J, Dembinska-Kiec A, Risérus U, Roche HM, Drevon CA, Birkeland KI.

Eur J Endocrinol. 2019 May 1;180(5):321-328. doi: 10.1530/EJE-19-0022.

PMID:
30893645
3.

Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment.

Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roché H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J, Campone M, Verrièle V, Lelièvre E, Guette C, Coqueret O.

Cell Death Dis. 2019 Feb 27;10(3):199. doi: 10.1038/s41419-019-1406-7.

4.

Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Puszkiel A, Arellano C, Vachoux C, Evrard A, Le Morvan V, Boyer JC, Robert J, Delmas C, Dalenc F, Debled M, Venat-Bouvet L, Jacot W, Suc E, Sillet-Bach I, Filleron T, Roché H, Chatelut E, White-Koning M, Thomas F.

Clin Pharmacol Ther. 2019 Feb 20. doi: 10.1002/cpt.1404. [Epub ahead of print]

PMID:
30786012
5.

Dietary modulation of energy homoeostasis and metabolic-inflammation.

Roche HM.

Proc Nutr Soc. 2019 Feb 1:1-6. doi: 10.1017/S0029665118002872. [Epub ahead of print]

PMID:
30704542
6.

Hydroxylase Inhibition Selectively Induces Cell Death in Monocytes.

Crifo B, Schaible B, Brown E, Halligan DN, Scholz CC, Fitzpatrick SF, Kirwan A, Roche HM, Criscuoli M, Naldini A, Giffney H, Crean D, Blanco A, Cavadas MA, Cummins EP, Fabian Z, Taylor CT.

J Immunol. 2019 Mar 1;202(5):1521-1530. doi: 10.4049/jimmunol.1800912. Epub 2019 Jan 30.

PMID:
30700584
7.

Dietary fat composition: replacement of saturated fatty acids with PUFA as a public health strategy, with an emphasis on α-linolenic acid.

Lenighan YM, McNulty BA, Roche HM.

Proc Nutr Soc. 2019 May;78(2):234-245. doi: 10.1017/S0029665118002793. Epub 2019 Jan 11.

PMID:
30630554
8.

SerpinA3N is a novel hypothalamic gene upregulated by a high-fat diet and leptin in mice.

Sergi D, Campbell FM, Grant C, Morris AC, Bachmair EM, Koch C, McLean FH, Muller A, Hoggard N, de Roos B, Porteiro B, Boekschoten MV, McGillicuddy FC, Kahn D, Nicol P, Benzler J, Mayer CD, Drew JE, Roche HM, Muller M, Nogueiras R, Dieguez C, Tups A, Williams LM.

Genes Nutr. 2018 Nov 29;13:28. doi: 10.1186/s12263-018-0619-1. eCollection 2018.

9.

Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism.

Hughes MF, Lenighan YM, Godson C, Roche HM.

Front Cardiovasc Med. 2018 Nov 6;5:148. doi: 10.3389/fcvm.2018.00148. eCollection 2018. Review.

10.

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).

Roché H, Eymard JC, Radji A, Prevost A, Diab R, Lamuraglia M, Soumoudronga RF, Gasnereau I, Toledano A.

BMC Cancer. 2018 Nov 16;18(1):1127. doi: 10.1186/s12885-018-4986-1.

11.

Nutritionally Derived Metabolic Cues Typical of the Obese Microenvironment Increase Cholesterol Efflux Capacity of Adipose Tissue Macrophages.

O'Reilly ME, Kajani S, Ralston JC, Lenighan YM, Roche HM, McGillicuddy FC.

Mol Nutr Food Res. 2019 Jan;63(2):e1800713. doi: 10.1002/mnfr.201800713. Epub 2018 Nov 20.

12.

Nutritional Modulation of AMPK-Impact upon Metabolic-Inflammation.

Lyons CL, Roche HM.

Int J Mol Sci. 2018 Oct 9;19(10). pii: E3092. doi: 10.3390/ijms19103092. Review.

13.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

Campone M, Lacroix-Triki M, Roca L, Spielmann M, Wildiers H, Cottu P, Kerbrat P, Levy C, Desmoulins I, Bachelot T, Winston T, Eymard JC, Uwer L, Duhoux FP, Verhoeven D, Jaubert D, Coeffic D, Orfeuvre H, Canon JL, Asselain B, Martin AL, Lemonnier J, Roché H.

Eur J Cancer. 2018 Nov;103:184-194. doi: 10.1016/j.ejca.2018.06.025. Epub 2018 Sep 26.

PMID:
30267987
14.

Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials.

Pistilli B, Mazouni C, Zingarello A, Faron M, Saghatchian M, Grynberg M, Spielmann M, Kerbrat P, Roché H, Lorgis V, Bachelot T, Campone M, Levy C, Gonçalves A, Lesur A, Veyret C, Vanlemmens L, Lemonnier J, Delaloge S.

Clin Breast Cancer. 2019 Feb;19(1):63-70. doi: 10.1016/j.clbc.2018.08.005. Epub 2018 Aug 23.

PMID:
30241966
15.

A proteomic signature that reflects pancreatic beta-cell function.

Curran AM, Scott-Boyer MP, Kaput J, Ryan MF, Drummond E, Gibney ER, Gibney MJ, Roche HM, Brennan L.

PLoS One. 2018 Aug 30;13(8):e0202727. doi: 10.1371/journal.pone.0202727. eCollection 2018.

16.

Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials.

Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, Patel A, Vahdat L.

Clin Breast Cancer. 2018 Dec;18(6):489-497. doi: 10.1016/j.clbc.2018.07.024. Epub 2018 Aug 4.

PMID:
30153978
17.

Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.

Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Gonçalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK.

Ann Oncol. 2018 Sep 1;29(9):1939-1947. doi: 10.1093/annonc/mdy257.

PMID:
30124753
18.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL.

N Engl J Med. 2018 Aug 23;379(8):753-763. doi: 10.1056/NEJMoa1802905. Epub 2018 Aug 15.

19.

Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.

Sarradin V, Dalenc F, Sibaud V, Tournier E, Roché H.

Clin Breast Cancer. 2018 Oct;18(5):e743-e746. doi: 10.1016/j.clbc.2018.06.009. Epub 2018 Jun 18. No abstract available.

PMID:
29980428
20.

Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.

Roche H, Bouiller K, Puzenat E, Deveza E, Roche B, Pelletier F, van de Laak A, Dupond AS, Nardin C, Aubin F.

J Dermatolog Treat. 2019 Apr 8:1-5. doi: 10.1080/09546634.2018.1480746. [Epub ahead of print]

PMID:
29848153
21.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H.

BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8.

22.

The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients.

Longué M, Cabarrou B, Wallet J, Brodowicz T, Roché H, Boher JM, Delord JP, Penel N, Filleron T.

Ann Oncol. 2018 Jul 1;29(7):1588-1593. doi: 10.1093/annonc/mdy168.

PMID:
29722789
23.

Personalized Cardio-Metabolic Responses to an Anti-Inflammatory Nutrition Intervention in Obese Adolescents: A Randomized Controlled Crossover Trial.

McMorrow AM, Connaughton RM, Magalhães TR, McGillicuddy FC, Hughes MF, Cheishvili D, Morine MJ, Ennis S, Healy ML, Roche EF, Tremblay RE, Szyf M, Lithander FE, Roche HM.

Mol Nutr Food Res. 2018 May;62(10):e1701008. doi: 10.1002/mnfr.201701008.

24.

Alternative methodological approach to randomized trial for surgical procedures routinely used.

Filleron T, Lusque A, Dalenc F, Ferron G, Roche H, Martinez A, Jouve E.

Contemp Clin Trials. 2018 May;68:109-115. doi: 10.1016/j.cct.2018.03.016. Epub 2018 Mar 30.

PMID:
29608972
25.

Mediterranean Diet, Glucose Homeostasis, and Inflammasome Genetic Variants: The CORDIOPREV Study.

Roncero-Ramos I, Rangel-Zuñiga OA, Lopez-Moreno J, Alcala-Diaz JF, Perez-Martinez P, Jimenez-Lucena R, Castaño JP, Roche HM, Delgado-Lista J, Ordovas JM, Camargo A, Lopez-Miranda J.

Mol Nutr Food Res. 2018 May;62(9):e1700960. doi: 10.1002/mnfr.201700960. Epub 2018 Apr 20.

PMID:
29573224
26.

Choosing a career in oncology: results of a nationwide cross-sectional study.

Faivre JC, Bibault JE, Bellesoeur A, Salleron J, Wack M, Biau J, Cervellera M, Janoray G, Leroy T, Lescut N, Martin V, Molina S, Pichon B, Teyssier C, Thureau S, Mazeron JJ, Roché H, Culine S.

BMC Med Educ. 2018 Jan 15;18(1):15. doi: 10.1186/s12909-018-1117-2.

27.

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.

Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A.

Cancer Res Treat. 2018 Oct;50(4):1226-1237. doi: 10.4143/crt.2017.446. Epub 2017 Dec 28.

28.

Proposed guidelines to evaluate scientific validity and evidence for genotype-based dietary advice.

Grimaldi KA, van Ommen B, Ordovas JM, Parnell LD, Mathers JC, Bendik I, Brennan L, Celis-Morales C, Cirillo E, Daniel H, de Kok B, El-Sohemy A, Fairweather-Tait SJ, Fallaize R, Fenech M, Ferguson LR, Gibney ER, Gibney M, Gjelstad IMF, Kaput J, Karlsen AS, Kolossa S, Lovegrove J, Macready AL, Marsaux CFM, Alfredo Martinez J, Milagro F, Navas-Carretero S, Roche HM, Saris WHM, Traczyk I, van Kranen H, Verschuren L, Virgili F, Weber P, Bouwman J.

Genes Nutr. 2017 Dec 15;12:35. doi: 10.1186/s12263-017-0584-0. eCollection 2017. Review.

29.

Breast cancer diagnostic assessment

Dalenc F, Pons E, Roche H.

Rev Prat. 2017 Nov 20;67(9):e453-e454. French. No abstract available.

PMID:
30717583
30.

Combining traditional dietary assessment methods with novel metabolomics techniques: present efforts by the Food Biomarker Alliance.

Brouwer-Brolsma EM, Brennan L, Drevon CA, van Kranen H, Manach C, Dragsted LO, Roche HM, Andres-Lacueva C, Bakker SJL, Bouwman J, Capozzi F, De Saeger S, Gundersen TE, Kolehmainen M, Kulling SE, Landberg R, Linseisen J, Mattivi F, Mensink RP, Scaccini C, Skurk T, Tetens I, Vergeres G, Wishart DS, Scalbert A, Feskens EJM.

Proc Nutr Soc. 2017 Nov;76(4):619-627. doi: 10.1017/S0029665117003949. Review.

PMID:
29137687
31.

Weighted Gene Co-Expression Network Analysis Identifies Gender Specific Modules and Hub Genes Related to Metabolism and Inflammation in Response to an Acute Lipid Challenge.

Fatima A, Connaughton RM, Weiser A, Murphy AM, O'Grada C, Ryan M, Brennan L, O'Gaora P, Roche HM.

Mol Nutr Food Res. 2018 Jan;62(2). doi: 10.1002/mnfr.201700388. Epub 2017 Dec 11.

PMID:
28952191
32.

Sexual Dimorphism, Age, and Fat Mass Are Key Phenotypic Drivers of Proteomic Signatures.

Curran AM, Fogarty Draper C, Scott-Boyer MP, Valsesia A, Roche HM, Ryan MF, Gibney MJ, Kutmon M, Evelo CT, Coort SL, Astrup A, Saris WH, Brennan L, Kaput J.

J Proteome Res. 2017 Nov 3;16(11):4122-4133. doi: 10.1021/acs.jproteome.7b00501. Epub 2017 Oct 4.

PMID:
28950061
33.

Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort.

O'Gorman A, Suvitaival T, Ahonen L, Cannon M, Zammit S, Lewis G, Roche HM, Mattila I, Hyotylainen T, Oresic M, Brennan L, Cotter DR.

Transl Psychiatry. 2017 Sep 26;7(9):e1240. doi: 10.1038/tp.2017.211.

34.

Processed red meat contribution to dietary patterns and the associated cardio-metabolic outcomes.

Lenighan YM, Nugent AP, Li KF, Brennan L, Walton J, Flynn A, Roche HM, McNulty BA.

Br J Nutr. 2017 Aug;118(3):222-228. doi: 10.1017/S0007114517002008.

PMID:
28831958
35.

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.

Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS.

Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. doi: 10.1016/j.clbc.2017.05.006. Epub 2017 May 22.

36.

Fatty Acids and NLRP3 Inflammasome-Mediated Inflammation in Metabolic Tissues.

Ralston JC, Lyons CL, Kennedy EB, Kirwan AM, Roche HM.

Annu Rev Nutr. 2017 Aug 21;37:77-102. doi: 10.1146/annurev-nutr-071816-064836. Review.

PMID:
28826373
37.

Effect of Dietary Lipids on Endotoxemia Influences Postprandial Inflammatory Response.

López-Moreno J, García-Carpintero S, Jimenez-Lucena R, Haro C, Rangel-Zúñiga OA, Blanco-Rojo R, Yubero-Serrano EM, Tinahones FJ, Delgado-Lista J, Pérez-Martínez P, Roche HM, López-Miranda J, Camargo A.

J Agric Food Chem. 2017 Sep 6;65(35):7756-7763. doi: 10.1021/acs.jafc.7b01909. Epub 2017 Aug 22.

PMID:
28793772
38.

APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome.

Fallaize R, Carvalho-Wells AL, Tierney AC, Marin C, Kieć-Wilk B, Dembińska-Kieć A, Drevon CA, DeFoort C, Lopez-Miranda J, Risérus U, Saris WH, Blaak EE, Roche HM, Lovegrove JA.

Sci Rep. 2017 Jul 24;7(1):6274. doi: 10.1038/s41598-017-05802-2.

39.

Nutritional modulation of metabolic inflammation.

Kirwan AM, Lenighan YM, O'Reilly ME, McGillicuddy FC, Roche HM.

Biochem Soc Trans. 2017 Aug 15;45(4):979-985. doi: 10.1042/BST20160465. Epub 2017 Jul 14. Review.

PMID:
28710289
40.

Clustering high-dimensional mixed data to uncover sub-phenotypes: joint analysis of phenotypic and genotypic data.

McParland D, Phillips CM, Brennan L, Roche HM, Gormley IC.

Stat Med. 2017 Dec 10;36(28):4548-4569. doi: 10.1002/sim.7371. Epub 2017 Jun 30.

PMID:
28664564
41.

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

Kerbrat P, Desmoulins I, Roca L, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain É, Serin D, Edel M, Debled M, Campone M, Mourret-Reynier MA, Bachelot T, Foucher-Goudier MJ, Asselain B, Lemonnier J, Martin AL, Roché H.

Eur J Cancer. 2017 Jul;79:166-175. doi: 10.1016/j.ejca.2017.03.004. Epub 2017 May 11.

PMID:
28501763
42.

Methodology of phase II clinical trials in metastatic elderly breast cancer: a literature review.

Cabarrou B, Mourey L, Dalenc F, Balardy L, Kanoun D, Roché H, Boher JM, Rougé-Bugat ME, Filleron T.

Breast Cancer Res Treat. 2017 Aug;164(3):505-513. doi: 10.1007/s10549-017-4278-5. Epub 2017 May 9. Review.

PMID:
28488143
43.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

44.

Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation.

Murphy AM, Thomas A, Crinion SJ, Kent BD, Tambuwala MM, Fabre A, Pepin JL, Roche HM, Arnaud C, Ryan S.

Eur Respir J. 2017 Apr 19;49(4). pii: 1601731. doi: 10.1183/13993003.01731-2016. Print 2017 Apr.

45.

Dietary fat quantity and quality modifies advanced glycation end products metabolism in patients with metabolic syndrome.

Lopez-Moreno J, Quintana-Navarro GM, Camargo A, Jimenez-Lucena R, Delgado-Lista J, Marin C, Tinahones FJ, Striker GE, Roche HM, Perez-Martinez P, Lopez-Miranda J, Yubero-Serrano EM.

Mol Nutr Food Res. 2017 Aug;61(8). doi: 10.1002/mnfr.201601029. Epub 2017 Mar 30.

PMID:
28233454
46.

Exploring the Links between Diet and Health in an Irish Cohort: A Lipidomic Approach.

O'Gorman A, Gibbons H, Ryan MF, Gibney ER, Gibney MJ, Frost GS, Roche HM, Brennan L.

J Proteome Res. 2017 Mar 3;16(3):1280-1287. doi: 10.1021/acs.jproteome.6b00912. Epub 2017 Feb 13.

PMID:
28145113
47.

Evaluation of the Theoretical Teaching of Postgraduate Radiation Oncology Medical Residents in France: a Cross-Sectional Study.

Faivre JC, Bibault JE, Leroy T, Agopiantz M, Salleron J, Wack M, Janoray G, Roché H, Culine S, Rivera S.

J Cancer Educ. 2018 Apr;33(2):383-390. doi: 10.1007/s13187-017-1170-2.

PMID:
28138918
48.

External validation of a published nomogram for prediction of brain metastasis in patients with extra-cerebral metastatic breast cancer and risk regression analysis.

Genre L, Roché H, Varela L, Kanoun D, Ouali M, Filleron T, Dalenc F.

Eur J Cancer. 2017 Feb;72:200-209. doi: 10.1016/j.ejca.2016.10.019. Epub 2016 Dec 30.

PMID:
28042991
49.

Behavioural biology: Stones that could cause ripples.

Roche H.

Nature. 2016 Nov 3;539(7627):34-35. doi: 10.1038/nature19484. Epub 2016 Oct 19. No abstract available.

PMID:
27760118
50.

Breast tumours

Dalenc F, Pons E, Roché H.

Rev Prat. 2017 Nov 20;67(9):e445-e454. French. No abstract available.

PMID:
30516922

Supplemental Content

Support Center